Welcome to our dedicated page for Trevi Therapeutics news (Ticker: $TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Trevi Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Trevi Therapeutics's position in the market.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) reported Q1 2024 financial results and business updates, reaffirming guidance for Phase 2a RIVER trial and HAP Study. Topline data for both trials expected in 2024. IND cleared for Phase 1b trial. Key business updates include progress in clinical trials, with Phase 2a RIVER trial and Phase 2b CORAL trial enrollment ongoing. The company ended Q1 2024 with $72.8 million in cash. Financially, R&D expenses increased to $8.8 million, G&A expenses were $3.1 million, with a net loss of $10.9 million. Conference call/webcast and upcoming meetings announced for investor participation.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) will host a conference call and webcast on May 7, 2024, to discuss the corporate update and financial results for the first quarter of 2024. The company is developing Haduvio™ for chronic cough in IPF and RCC. Investors can participate via phone or webcast.
